ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 232 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2021. The put-call ratio across all filers is 8.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,633 | -22.7% | 158 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $7,289 | +15.0% | 158 | 0.0% | 0.00% | +33.3% |
| Q1 2023 | $6,336 | +92.6% | 158 | +122.5% | 0.00% | +50.0% |
| Q4 2022 | $3,289 | +9.6% | 71 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | -25.0% | 71 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $4,000 | +33.3% | 71 | +91.9% | 0.00% | 0.0% |
| Q4 2021 | $3,000 | 0.0% | 37 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $3,000 | -25.0% | 37 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $4,000 | 0.0% | 37 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $4,000 | -33.3% | 37 | -22.9% | 0.00% | -50.0% |
| Q4 2020 | $6,000 | +50.0% | 48 | -43.5% | 0.00% | +33.3% |
| Q3 2019 | $4,000 | -33.3% | 85 | -9.6% | 0.00% | -25.0% |
| Q2 2019 | $6,000 | -14.3% | 94 | 0.0% | 0.00% | -20.0% |
| Q1 2019 | $7,000 | 0.0% | 94 | -3.1% | 0.01% | +66.7% |
| Q3 2018 | $7,000 | – | 97 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |